Collegium Pharmaceutical (COLL) vs Rigel Pharmaceuticals (RIGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rigel Pharmaceuticals (RIGL) has outperformed Collegium Pharmaceutical (COLL) over the past year, losing 13.3% versus a loss of 45.2%. Over five years, RIGL leads with a +44.7% price change compared with +37.7% for COLL. Collegium Pharmaceutical is the larger company by market cap ($768.2 million vs $754.9 million), about 1.0 times the size, while Rigel Pharmaceuticals is growing revenue faster (+64.1% vs +23.6%).
On valuation, Collegium Pharmaceutical trades at a lower forward P/E (3.5x vs 8.4x for Rigel Pharmaceuticals). Rigel Pharmaceuticals converts more of its revenue into profit, with a net margin of 124.7% versus 8.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | RIGL |
|---|---|---|
| Share price | $24.72 | $40.09 |
| Market cap | $768.18M | $754.89M |
| 1-day change | -1.94% | -2.67% |
| YTD return | -46.61% | -6.40% |
| 1-year return | -45.24% | -13.26% |
| 5-year return | +37.72% | +44.73% |
| P/E ratio (TTM) | 22.68 | 2.49 |
| Forward P/E | 3.49 | 8.39 |
| EPS (TTM) | $1.09 | $16.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $780.57M | $294.28M |
| Revenue growth (YoY) | +23.62% | +64.15% |
| Net income (latest FY) | $62.87M | $367.02M |
| Gross margin | 59.35% | 93.33% |
| Operating margin | 23.01% | 42.63% |
| Net margin | 8.05% | 124.72% |
| 52-week high | $50.79 | $52.61 |
| 52-week low | $21.43 | $24.95 |
| Distance from 52-week high | -51.33% | -23.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +77.99% | +60.64% |
| Average volume | 754.45K | 248.06K |
| Shares outstanding | 31.08M | 18.83M |
| Employees | 423 | 172 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RIGL has outperformed COLL by 32.0 percentage points over the past year.
- Collegium Pharmaceutical trades at a higher earnings multiple (22.7x vs 2.5x trailing P/E).
- Rigel Pharmaceuticals is more profitable, keeping 124.7 cents of every revenue dollar as net income versus 8.1 cents for Collegium Pharmaceutical.
- Rigel Pharmaceuticals grew revenue faster in its latest fiscal year (+64.15% vs +23.62%).
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Rigel Pharmaceuticals
RIGL stock →Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 172 employees
COLL vs RIGL FAQ
Which is bigger, Collegium Pharmaceutical or Rigel Pharmaceuticals?
Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $768.18M compared with $754.89M for Rigel Pharmaceuticals (RIGL).
Which stock has performed better over the past year, COLL or RIGL?
RIGL returned -13.26% over the past 12 months, compared with -45.24% for COLL (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, COLL or RIGL?
RIGL has the lower trailing P/E at 2.5, versus 22.7 for COLL. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Collegium Pharmaceutical and Rigel Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.